fondaparinux / Generic mfg. - LARVOL DELTA

Case Report: A multidisciplinary, protocol-driven pathway from recurrent pregnancy loss to live birth in an anti-Ro/SSA-positive primary Sjögren's syndrome pregnancy with literature review. (PubMed, Front Immunol) - "A multidisciplinary protocol was implemented, including hydroxychloroquine 400 mg/day, methylprednisolone (initially 6 mg/day, briefly increased to 32 mg/day at 14-16 weeks, then tapered to 8 mg/day), low-dose aspirin 50 mg/day, and fondaparinux 2.5 mg/day from ovulation throughout pregnancy, along with scheduled intravenous immunoglobulin (IVIG; 20 g at 4, 6 + 6, and 8 + 2 weeks; followed by 20 g/day × 3 at 14, 18, and 22weeks)...Postpartum, the mother continued methylprednisolone 6 mg/day, hydroxychloroquine 400 mg daily, and enoxaparin 4,000 IU once daily for 4 weeks maintain disease suppression and thromboprophylaxis. In an anti-Ro/SSA-positive pregnancy at extreme risk, a prevention-first, protocol-driven approach-centered on hydroxychloroquine, judicious immunomodulation, and structured AV-interval surveillance-successfully averted CAVB and resulted in a pacemaker-free live birth. Minor cardiac lesions warrant ongoing follow-up;..."

Journal • Review • Cardiovascular • CNS Disorders • Hematological Disorders • Hypertension • Immunology • Inflammatory Arthritis • Lupus • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Sjogren's Syndrome

Complexities of Anticoagulants and Reversal Agents on VADs (ISHLT 2026) - "Direct thrombin inhibitors, Heparin, Warfarin and Fondaparinux will be discussed, as well as Andexanant and prothrombin concentrate complex. A case presentation will highlight antithrombotic choice and reversal strategy: pausing, or reversal agent and associated risks. A 5-minute audience Q&A will follow."

Current Trends in Venous Thromboprophylaxis for Inpatient Care. (PubMed, J Pers Med) - "The aim of the present review is to provide a structured synthesis of the current evidence on thromboprophylaxis strategies in hospitalized patients, critically appraise the performance and applicability of existing VTE and bleeding risk models and highlight how these tools can guide a tailored illness-specific approach to prophylactic decision-making. Where relevant, the review also outlines practical, risk-adapted algorithms to optimize thromboprophylaxis across diverse clinical settings."

Journal • Review • Cardiovascular • Hematological Disorders • Venous Thromboembolism

Safety Profile and Bleeding Complications of Fondaparinux Versus Enoxaparin in Non-ST Elevation Acute Coronary Syndrome. (PubMed, Cureus) - "Conclusions Fondaparinux demonstrates superior safety and effectiveness over enoxaparin in reducing bleeding complications and ischemic events among NSTE-ACS patients. These findings support its preferential use in resource-constrained clinical settings."

Journal • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Diabetes • Heart Failure • Hypertension • Metabolic Disorders • Myocardial Infarction

Fondaparinux-associated thrombocytopenia as a cause of bilateral pulmonary embolism. (PubMed, Med Clin (Barc)) - No abstract available

Journal • Cardiovascular • Hematological Disorders • Pulmonary Embolism • Respiratory Diseases • Thrombocytopenia

Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial. (PubMed, JAMA) - P=N/A | "Physicians and patients selected any DOAC or any LMWH (or fondaparinux) and physicians selected drug doses...These findings support use of a DOAC to prevent recurrent VTE in patients with cancer. ClinicalTrials.gov Identifier: NCT02744092."

Clinical • Journal • Cardiovascular • Chronic Lymphocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Oncology • Solid Tumor • Venous Thromboembolism

EFFICACY AND SAFETY OF DOACS FOR THE TREATMENT OF SUPERFICIAL VEIN THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. (PubMed, Thromb Haemost) - "DOACs demonstrate efficacy comparable to fondaparinux and an excellent safety profile in SVT, supporting their use as a practical oral alternative. Long-term data indicate persistent thrombotic risk, suggesting potential benefit of extended low-dose prophylaxis in selected high-risk patients."

Journal • Retrospective data • Cardiovascular • Hematological Disorders • Respiratory Diseases • Thrombosis • Venous Thromboembolism

Rational design of heparin antagonist: Guanidine-based mimetics unveil key carbohydrate-carbohydrate interactions. (PubMed, Eur J Med Chem) - "When evaluated as potential antidotes for heparin and fondaparinux-mediated blood coagulation, the highly guanidine-substituted HP mimetics displayed sub-micromolar antagonist potency. NMR studies further confirmed the carbohydrate-carbohydrate interactions between fondaparinux and the HP mimetics, providing a mechanistic basis for the observed activity and introducing a new strategy to block HP-mediated biological functions."

Journal • Oncology

MERCURION-IPF: Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P3 | N=196 | Not yet recruiting | Sponsor: Argyrios Tzouvelekis

New P3 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

The Necessity to Provide an Informed Choice Regarding Venous Thromboembolism Prophylaxis: A Single-Centre Study Observing Clinician Adherence and Opinions on Venous Thromboembolism Prophylaxis. (PubMed, Cureus) - "These are often done via nonpharmacological methods, such as anti-embolic (TED™) stockings, or with pharmacological methods, such as low molecular weight heparin (LMWH), which consists of medications such as dalteparin...Fondaparinux sodium, a fully synthetic alternative, offers a non-animal-derived option, yet its use remains limited...This demonstrates a clear health inequality. Educational initiatives and institutional protocols are recommended to promote patient-centred care and ensure ethical prescribing consistent with individual values."

Journal • Cardiovascular • Venous Thromboembolism

When pregnancy, HIT, and stroke collide: Navigating complex thrombotic care in a community-based setting (ASH 2025) - "Case Presentation: A 30-year-old woman, gravida 1 para 0, with a history of unprovoked lower extremity deep vein thrombosis (DVT) on chronic rivaroxaban for secondary prophylaxis was transitioned to low-molecular-weight heparin (enoxaparin) upon confirmation of pregnancy at 7 weeks' gestation...Enoxaparin was discontinued, and argatroban was initiated post-EVT, later transitioning to subcutaneous danaparoid, and ultimately fondaparinux for the remainder of her pregnancy...Another important feature of this case is that it was successfully managed entirely within a regional community hospital system, allowing the patient to stay close to her family and access local rehabilitation services. This case report highlights the ability of community-based hospitals to provide high-acuity, patient-centered care through strong interdisciplinary collaboration."

Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombocytopenia • Thrombosis

Platelet dynamics and clinical outcomes in patients with heparin-induced thrombocytopenia – single center experience (ASH 2025) - "Several agents, such as bivalirudin, argatroban, danaparoid, and fondaparinux, have been used for the treatment of HIT. The dynamics of platelet counts after diagnosis may be an important tool for assessing treatment efficacy. Despite treatment, the mortality rate in critically ill patients with HIT remains high."

Clinical • Clinical data • Cardiovascular • Hematological Disorders • Thrombocytopenia

Heparin-induced thrombocytopenia after percutaneous coronary intervention complicated by hemothorax and pulmonary thromboembolism: The scylla and charybdis of hematology (ASH 2025) - "Those with a confirmed diagnosis need to be started on therapeutic-dose anticoagulation with argatroban, danaparoid, bivalirudin, or fondaparinux. Our case highlights a unique case of HIT with both thrombosis and life-threatening bleeding post-PCI that precluded the use of both anticoagulation and antiplatelets, underscoring the complexity of care, need for a multidisciplinary approach, and individualization of treatment in such cases."

Cardiovascular • Cerebral Hemorrhage • Chronic Kidney Disease • Diabetes • Endocrine Disorders • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Thrombocytopenia

HIT or miss?: Long-term outcomes of direct thrombin inhibitors vs fondaparinux use in heparin-induced thrombocytopenia (ASH 2025) - "Cohort A had 1489patients diagnosed with HIT and treated with fondaparinux while Cohort B had 1489 patients diagnosedwith HIT and treated with direct thrombin inhibitors (argatroban, bivalirudin, lepirudin or desirudin). Our study provides evidence that fondaparinux significantly reduces the risk of mortality and adverseevents including myocardial infarction, skin necrosis, arterial embolism/thrombosis and moderate tosevere thrombocytopenia at one year compared to DTIs for the management of HIT. In addition to theseclinical benefits, fondaparinux offers cost advantages and ease of use, with its subcutaneousadministration, predictable pharmacokinetics, and minimal need for laboratory monitoring making itparticularly useful in outpatient and resource-limited settings. However, fondaparinux carries anincreased risk of major bleeding, particularly intracranial hemorrhage, due to the lack of a reversal agent.It is also contraindicated in patients with renal impairment and..."

Acute Kidney Injury • Cerebral Hemorrhage • Chronic Kidney Disease • CNS Disorders • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Fibrosis • Gastroenterology • Genetic Disorders • Heart Failure • Hematological Disorders • Hepatology • Immunology • Ischemic stroke • Liver Cirrhosis • Metabolic Disorders • Myocardial Infarction • Nephrology • Obesity • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Thrombocytopenia

Cost effectiveness of in-house HIT screening testing in community based hospital (ASH 2025) - "Empiric anticoagulation was initiated in 147 (28.8%) patients, withargatroban in 85 (57.8%), fondaparinux in 50 (34.0%), and 12 (8.2%) receiving other anticoagulants(apixaban, rivaroxaban, or bivalirudin)...Only 48 (18.6%) patients received empiricanticoagulation, with argatroban used in 25 (52.1%), fondaparinux in 17 (35.4%), and otheranticoagulants (apixaban and bivalirudin) in 6 (12.5%)...Theimplementation of in-house HIT screening tests resulted in an annual cost saving of $17,181 inanticoagulation alone. ConclusionImplementation of the HIT testing algorithm using an in-house screening test with a reflex outsourcedconfirmatory test resulted in decreased turnaround time, reduction of empiric anticoagulation utilization,and potential cost savings for hospitalized patients with suspected HIT."

Clinical • Cost effectiveness • HEOR • Hematological Disorders • Thrombocytopenia

Association between the Use of Fondaparinux Plus Radial Access and Clinical Outcomes in Patients with Non-ST Elevation Acute Coronary Syndrome. (PubMed, Arq Bras Cardiol) - "The combination of fondaparinux and radial access was associated with the lowest rates of MACE and major bleeding, compared to either strategy alone."

Clinical data • Journal • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

Radial Access and Fondaparinux: A Synergistic Interaction. (PubMed, Arq Bras Cardiol) - No abstract available

Journal

Graduated Compression Stockings for Thromboprophylaxis in Orthopaedic and Trauma Surgery: A Rapid Review and Meta-Analysis. (PubMed, J Clin Med) - "Seven studies (N = 5117) compared various combinations of pharmacological prophylaxis, with or without gCS, for a summary RR of 1.44 (95% CI: 0.76-2.72). The results of this rapid review neither show a clear benefit nor support the general use of gCS to prevent TE in orthopaedic and trauma surgery, especially if pharmacological prophylactic measures are established and suitable."

Journal • Retrospective data • Review • Cardiovascular • Hematological Disorders • Musculoskeletal Diseases • Orthopedics • Pulmonary Embolism • Respiratory Diseases

Preferences Among Expert Physicians in Areas of Uncertainty in Venous Thromboembolism Management: Results from a Multiple-Choice Questionnaire. (PubMed, J Clin Med) - "Respondents considered the following to be appropriate: risk assessment of VTE (93.44%) and bleeding (91.6%) in hospitalized medical patients; low-molecular weight heparin (LMWH) prophylaxis for inpatients with pneumonia and malignancy (82.78%); therapeutic doses of LMWH/fondaparinux in patients with intermediate/high risk of PE with (80.9%) or without (77.97%) instability criteria; and echocardiography to manage patients with a post-PE syndrome (93.99%). Respondents considered the following to be inappropriate: use of 4000 IU LMWH in chronic renal failure (80.46%); use of 2000 IU LMWH in persons on dual antiplatelet therapy (77.01%); and use of low-dose apixaban (2.5 mg) in pregnancy (88.57%) or in subsegmental PE with hypoxemia (82.46%)... Our findings show persistent gaps between guideline recommendations and clinical implementation despite improved awareness among physicians. Uncertainty persists regarding criteria for outpatient PE eligibility and/or for validation..."

Journal • Cardiovascular • Chronic Kidney Disease • Hematological Disorders • Infectious Disease • Oncology • Pneumonia • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Venous Thromboembolism

Comparative Effectiveness and Safety of Various Anticoagulation Regimens for Portal Venous Thrombosis in Cirrhosis: A Systematic Review and Network Meta-Analysis. (PubMed, Clin Appl Thromb Hemost) - "DOACs significantly decreased mortality (RR = 0.74; 95% CI: [0.67, 0.81]; p < 0.0001), with LMWH ranked highest (P-score = 0.80) for mortality.ConclusionDOACs, LMWH, and LMWH-Warfarin sequential therapy significantly improved recanalization and reduced PVT progression. LMWH was ranked highest in reducing bleeding and mortality, while fondaparinux ranked highest regarding esophageal bleeding and complete recanalization."

Clinical • HEOR • Journal • Retrospective data • Review • Cardiovascular • Fibrosis • Gastroenterology • Hematological Disorders • Hepatology • Immunology • Liver Cirrhosis • Thrombosis

Efficacy and safety of tranexamic acid combined with low molecular weight heparin versus fondaparinux sodium following total knee arthroplasty: a retrospective cohort study. (PubMed, Front Pharmacol) - "Both regimens showed comparable efficacy in managing perioperative blood loss, operative time, hospital stay, and transfusion requirements in TKA patients. Given the retrospective design and limited sample size, further validation through high-quality, large-scale prospective studies is warranted."

Journal • Retrospective data • Acute Kidney Injury • Cardiovascular • CNS Disorders • Epilepsy • Hematological Disorders • Immunology • Infectious Disease • Orthopedics • Osteoarthritis • Pain • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Rheumatology • Thrombosis

Influence of heparin-based anticoagulants on antibiotic therapy. (PubMed, Front Immunol) - "Given the prevalence of negatively charged anticoagulants in clinical settings, we aimed to explore the effects of unfractionated heparin, low molecular weight heparin, and fondaparinux on the antibacterial activity of AMCs and antibiotics (colistin, daptomycin, gentamicin, imipenem, ofloxacin, and vancomycin). These findings support our hypothesis that specific heparin-based anticoagulants interfere with the activity of blood-derived AMCs and positively charged antibiotics, reducing their efficacy in vitro. Our research aims to provide a foundation for future studies focused on optimizing anticoagulant use in clinical settings, ultimately improving patient outcomes in the ongoing fight against multidrug-resistant bacteria."

Journal • Infectious Disease

Alternative Anticoagulation for Patients with Heparin-Induced Thrombocytopenia on ECMO: A Narrative Review. (PubMed, Biomedicines) - "Most available data, primarily from retrospective studies, describe the use of argatroban in ECMO patients with HIT. Bivalirudin has also been used as an alternative anticoagulant in this population, with no significant increase in bleeding or thrombotic complications...Fondaparinux has shown effectiveness in the HIT setting and appears to have a low risk of complications. Factor XIIa inhibitors represent a novel class of anticoagulants currently under investigation, evaluated only in animal models. Growing clinical experience with alternative anticoagulants, particularly direct thrombin inhibitors, suggests that their use will likely become a primary focus in ECMO anticoagulation management in the coming years."

Journal • Review • Cardiovascular • Critical care • Hematological Disorders • Thrombocytopenia • Thrombosis

HIPSTER-Pilot: Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention (clinicaltrials.gov) - P3 | N=100 | Not yet recruiting | Sponsor: McMaster University

New P3 trial • Cardiovascular • Musculoskeletal Diseases • Orthopedics • Venous Thromboembolism

Risk Factors Associated with Anticoagulant-Related Bleeding in Patients with Cancer-Associated Thrombosis (ASH 2023) - "Most patients received anticoagulant therapy with LMWH (47.7%), followed by DOACs (26.8%), VKAs (24.5%), and fondaparinux (1%)... In this study, many candidate variables in available risk prediction models for anticoagulant-related bleeding were not associated with bleeding risk. This may explain the performance of these models in patients with cancer on anticoagulant therapy. We identified cancer-specific candidate variables that were associated with risk of anticoagulant-related bleeding."

Clinical • Addiction (Opioid and Alcohol) • Anemia • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastrointestinal Cancer • Genito-urinary Cancer • Hematological Disorders • Hepatology • Hypertension • Ischemic stroke • Oncology • Thrombosis • Venous Thromboembolism